Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Open access

Abstract

Overall survival analysis combining LUX-Lung 3 and LUX-Lung 6.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)71173-8

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Wu, 2013, First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analyses from the Phase 3, open-label, ENSURE study, J Thorac Oncol, 8, S603
  2. Ding, 2013, Exon 19 deletions, smoking history and gender as additional predictive factors for treatment benefit with EGFR tyrosine kinase inhibitors in patients harbouring activating EGFR mutations: a meta-analysis of 1432 patients in six randomised trials, J Thorac Oncol, 8

Cited by

See all 1,586

Metadata

Authors
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., Lu, S., Huang, Y., Geater, S. L., Lee, K. Y., Tsai, C.-M., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., Mok, T., Boyer, M., Su, W.-C., Lee, K. H., Kato, T., Massey, D., Shahidi, M., Zazulina, V., & Sequist, L. V.
Affiliations
  • National Taiwan University (TW)
  • Guangdong General Hospital (CN)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Royal Marsden Hospital (GB)
  • Wakayama Medical University (JP)
  • Tongji University (CN)
  • Central South University (CN)
  • Queensland University of Technology (AU)
  • Jiangsu Cancer Hospital (CN)
  • Kunming Medical University (CN)
  • Prince of Songkla University (TH)
  • Chungbuk National University (KR)
  • Taipei Veterans General Hospital (TW)
  • McGill University (CA)
  • Institut de Cancérologie de l'Ouest (FR)
  • Chinese University of Hong Kong (HK)
  • Royal Prince Alfred Hospital (AU)
  • National Cheng Kung University Hospital (TW)
  • Kanagawa Cardiovascular and Respiratory Center (JP)
  • Boehringer Ingelheim (United Kingdom) (GB)
  • Harvard University (US)
Corresponding author
Yang, James Chih-Hsin
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-02
Volume
16
Issue
2
Pages
141-151
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2132870547
Cited by
1,574
References
30
Citations by year
2026: 33 · 2025: 67 · 2024: 72 · 2023: 107 · 2022: 129 · 2021: 159 · 2020: 148 · 2019: 165 · 2018: 165 · 2017: 201 · 2016: 201 · 2015: 125
FWCI
182.17
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by-nc-nd)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
afatinib, EGFR tyrosine kinase inhibitors, gemcitabine-cisplatin chemotherapy, overall survival, EGFR exon 19 deletion, advanced non-small cell lung cancer
MeSH terms
Pemetrexed, Afatinib, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Deoxycytidine, Female, Follow-Up Studies, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Quinazolines, Survival Rate, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71173-8
The paper
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., Lu, S., Huang, Y., Geater, S. L., Lee, K. Y., Tsai, C.-M., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., . . . Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71173-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.